biostudies-literatureUnknown19(6)Lu J<h4>Objective</h4>Sarcomas are a group of rare malignancies with various subtypes. Patients with metastatic sarcoma who have failed traditional treatments can possibly achieve better prognoses from using novel therapies, including anti-programmed death-1 (PD-1)-based therapies.<h4>Methods</h4>We retrospectively analyzed clinical data of 24 metastatic sarcoma patients from June 15, 2016 to December 30, 2019. These patients mainly received angiogenesis inhibitors combined with anti-PD-1 therapy after they became resistant to traditional treatments. Furthermore, 8 patients underwent panel DNA and whole transcript sequencing.<h4>Results</h4>Six patients received 2 cycles of anti-PD-1 therapy and were included in the safety evaluation only group. The median follow-up time was 5.77 months. The mCancer biology & medicinej.issn.2095-3941.2021.0270https://www.ebi.ac.uk/biostudies/studies/S-EPMC9257312biostudies-literatureThe efficacies and biomarker investigations of antiprogrammed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma.PMC9257312Liao ZTrent JYang JTeng SChen KRen ZYu HZhao YWu HLi XYang YLi TLu JXing RZhao JfalseThe efficacies and biomarker investigations of antiprogrammed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma.<h4>Objective</h4>Sarcomas are a group of rare malignancies with various subtypes. Patients with metastatic sarcoma who have failed traditional treatments can possibly achieve better prognoses from using novel therapies, including anti-programmed death-1 (PD-1)-based therapies.<h4>Methods</h4>We retrospectively analyzed clinical data of 24 metastatic sarcoma patients from June 15, 2016 to December 30, 2019. These patients mainly received angiogenesis inhibitors combined with anti-PD-1 therapy after they became resistant to traditional treatments. Furthermore, 8 patients underwent panel DNA and whole transcript sequencing.<h4>Results</h4>Six patients received 2 cycles of anti-PD-1 therapy and were included in the safety evaluation only group. The median follow-up time was 5.77 months. The m2021-01-01T00:00:00Z2021 Nov2026-05-09T23:42:15.512Z2025-04-04T22:12:19.204ZS-EPMC92573123481795010.20892/j.issn.2095-3941.2021.0270